Final answer:
Jardiance can be used in adult patients with Stage 4 chronic kidney disease (CKD), where eGFR is as low as 20 mL/min/1.73 m². This medication helps manage Type 2 diabetes even in the context of severe reduction in kidney function, although it's not recommended for Stage 5 CKD.
Step-by-step explanation:
Jardiance, a medication used to treat Type 2 diabetes, may be initiated or continued in adult patients with chronic kidney disease (CKD). Its use is permissible even with a estimated glomerular filtration rate (eGFR) as low as 20 mL/min/1.73 m², which falls within Stage 4 CKD. Patients in this severe reduction stage of kidney function have an eGFR between 15-29 mL/min/1.73 m². It's important to manage diabetes effectively in patients with CKD as part of an overall strategy to prevent further kidney damage.
For context, CKD is typically identified in stages, with Stage 3 representing a moderate reduction in kidney function, where eGFR is between 30-59 mL/min/1.73 m². By comparison, Stage 5 CKD is characterized by established kidney failure or a GFR less than 15 mL/min/1.73 m², and usually requires renal replacement therapy. Jardiance is not recommended for patients with Stage 5 CKD due to the inadequate kidney function.